Continuous plasmafiltration in sepsis syndrome
- 1 October 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 27 (10) , 2096-2104
- https://doi.org/10.1097/00003246-199910000-00003
Abstract
To assess the effect of plasmafiltration (PF) on biochemical markers of inflammation, cytokines, organ dysfunction, and 14-day mortality in human sepsis. Multicenter, prospective, randomized, controlled clinical trial. Seven university-affiliated intensive care units. Thirty patients (22 adults, eight children) with new (<24 hrs) clinical evidence of infection and sepsis syndrome were enrolled. Fourteen of 30 (nine adults, five children) were randomized to PF. All patients received protocol-driven supportive intensive care, and those randomized to PF received continuous plasma exchange for 34 hrs using a hollow-fiber plasma filter. Illness severity and risk of death were calculated with the Pediatric Risk of Mortality (children) and the Acute Physiology and Chronic Health Evaluation II (adults) scales. Plasma samples (0, 6, 24, and 48 hrs) were assayed for acute-phase proteins (albumin, globulin, C-reactive protein, α1-antitrypsin, haptoglobin), inflammatory mediators (complement fragment C3, thromboxane B2), and cytokines (interleukin-6, granulocyte colony-stimulating factor, leukemia inhibitory factor). Sieving coefficients were estimated from filtrate concentrations at 3 hrs. The two groups were matched for incidence of septic shock (13 of 14 vs. 11 of 16), refractory shock (three of 14 vs. six of 16), bacteremia (six of 14 vs. five of 16), severity of illness, and calculated risk of death (0.68 vs. 0.64). There was no difference in mortality. Eight of 14 PF patients (57%) and eight of 16 controls (50%) survived for 14 days (p = .73, Fisher's exact test). Multiple logistic regression revealed age (odds ratio, 16.4:1; 95% confidence interval, 2.12-∞) and shock (10.6:1; 1.32-∞) as significant predictors of death; plasmafiltration was associated with a nonsignificant reduction in the risk of death (odds ratio, 1.78:1; 95% confidence interval, 0.20-18.1). The mean (SD) number of organs failing in the first 7 days in the PF group was 2.57 (0.94) vs. 2.94 (0.85) in controls (p = .37, Mann-Whitney U test). Both groups had similarly elevated plasma concentrations of all inflammatory mediators except complement fragment C3 at study entry. Leukemia inhibitory factor was detectable in four patients only. PF did not influence mean concentrations of interleukin-6, granulocyte colony-stimulating factor, thromboxane B2, total white cell count, neutrophil count, or platelet count, but it was associated with significant reductions of α1-antitrypsin, haptoglobin, C-reactive protein, and complement fragment C3 in the first 6 hrs (p < .05). The sieving coefficients for all inflammatory mediators approached unity. PF caused a significant attenuation of the acute-phase response in sepsis. There was no significant difference in mortality, but there was a trend toward fewer organs failing in the PF group that suggests that this procedure might be beneficial.Keywords
This publication has 52 references indexed in Scilit:
- Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shockCritical Care Medicine, 1996
- A second large controlled clinical study of E5, a monoclonal antibody to endotoxinCritical Care Medicine, 1995
- The Natural History of the Systemic Inflammatory Response Syndrome (SIRS)JAMA, 1995
- Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCritical Care Medicine, 1994
- Introduction of new technology into critical care practiceCritical Care Medicine, 1993
- Pathogenetic Mechanisms of Septic ShockNew England Journal of Medicine, 1993
- Immunologic Therapy for ARDS, Septic Shock, and Multiple-Organ FailureChest, 1993
- Cost-effectiveness of HA-1A Monoclonal Antibody for Gram-Negative SepsisPublished by American Medical Association (AMA) ,1991
- Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic SepsisNew England Journal of Medicine, 1987
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987